Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced its preliminary sales results for Q4 2022, reporting GAAP sales of
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will present an update on Wednesday, January 11, 2023, at 8:15 PM Eastern Time. The presentation will be available via a live webcast, with an archived recording accessible for 30 days on the company’s Investor Center website. Tandem Diabetes Care focuses on innovative insulin delivery solutions and is known for its t:slim X2 insulin pump featuring Control-IQ technology.
Tandem Diabetes Care (TNDM) has announced its definitive agreement to acquire AMF Medical, the Swiss developer of the Sigi™ Patch Pump. This acquisition is expected to expand Tandem's addressable market for insulin delivery solutions and enhance its product portfolio. The deal includes an initial payment of CHF 62.4 million, in addition to contingent earnout payments totaling up to CHF 129.6 million based on milestone achievements. The acquisition aims to accelerate product development, reduce waste, and offer additional customer access, with the transaction expected to close in January 2023.
Tandem Diabetes Care (NASDAQ: TNDM) has achieved the Great Place to Work Certification, with 84% of employees affirming it’s a great workplace, significantly higher than the national average. This recognition, based on employee feedback, highlights Tandem's commitment to a positive workplace culture, aligning with its core value of People First. The company has gained local accolades in San Diego and Boise for its work environment, emphasizing its focus on employee satisfaction.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced positive results from a multicenter study on the t:slim X2 insulin pump featuring Control-IQ technology for type 2 diabetes management. The study found significant improvements in glycemic control, with a 15% increase in time in range (3.6 hours/day). No hypoglycemia was reported. High satisfaction levels were observed among participants. The trial involved 30 adults across three centers. Notably, Control-IQ technology is not yet FDA-approved for type 2 diabetes use and was employed under an investigational device exemption.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leader in diabetes technology, will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022, at 9:00 AM Eastern Time. The presentation will be available via live webcast, and an archive will be accessible for 30 days. More details can be found on Tandem's Investor Center under the “Events & Presentations” section. Tandem is known for its innovative insulin delivery solutions, including the t:slim X2 insulin pump.
Tandem Diabetes Care reported its Q3 2022 results, highlighting a 35% increase in its worldwide installed customer base, surpassing 400,000. Total sales rose 14% to $204.5 million, driven by a nearly 70% surge in U.S. renewal pump shipments. Despite a gross profit increase of 8% to $104.4 million, the company faced a GAAP net loss of $49 million, compared to a profit in the prior year. The updated 2022 guidance estimates non-GAAP sales between $800 million and $805 million, down from previous expectations, amid cautious market conditions.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present updates at several investor conferences in November 2022. The presentations will take place at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 4:25 PM ET, the Jefferies London Healthcare Conference on November 15 at 12:20 PM GMT, and the Stifel 2022 Healthcare Conference on November 16 at 4:45 PM ET. All presentations will be webcast live with an archive available for 30 days on their Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to announce its third quarter 2022 results post-market close on November 2, 2022. A conference call and webcast, scheduled for 4:30 PM ET, will discuss the financial and operational results. Investors can access the live webcast via the Investor Center on their website. An archived version will be available for 30 days following the event.
As a prominent insulin delivery and diabetes technology firm, Tandem continues to innovate with products like the t:slim X2 insulin pump featuring Control-IQ technology.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present at two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 8, 2022, at 1:55 PM ET and Baird’s Global Healthcare Conference on September 13, 2022, at 9:40 AM ET. Both presentations will be webcast live, with archived recordings available for 30 days on their Investor Center website. Tandem focuses on innovative diabetes solutions, offering products like the t:slim X2 insulin pump with Control-IQ technology.
FAQ
What is the current stock price of Tandem Diabetes Care (TNDM)?
What is the market cap of Tandem Diabetes Care (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
